IntelGenx (TSXV:IGX; OTCQX:IGXT) said the European Patent Office (EPO) has issued a notice of intention to grant the first key patent allowed in Europe for the company’s VersaFilm technology. The patent is entitled...
Ortho Regenerative Technologies (CSE:ORTH) reported positive outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from Montreal’s École...
IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a peer-reviewed paper entitled, “2018 Alzheimer’s Disease Facts and Figures,” published in the March 2018 issue of Alzheimer’s & Dementia: The Journal of the...
Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn agreed to terminate a December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Under the...
Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma...
Cara Therapeutics (NASDAQ:CARA) licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in...
Closely-held Beta Bionics received FDA approval to begin home-use clinical studies of an autonomous bionic pancreas that employs artificial intelligence to vary hormone doses in adults and children with Type 1 diabetes...
Nabriva Therapeutics (NASDAQ:NBRV) reported positive top-line results from its LEAP 2 clinical trial, the second of two global, Phase 3 clinical trials of its antibiotic, lefamulin. LEAP 2 evaluated the safety and...
Closely-held Tear Film Innovations completed an $8.5-million Series B preferred stock round led by Visionary Ventures Fund and Bluestem Capital. “This successful funding round completes the capitalization for our growth...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) presented positive initial data from its TACT pivotal study with its TULSA-PRO ablation device at the American Urological Association (AUA) annual meeting in San Francisco. The...